| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Rosetta Genomics Ltd
Rosetta Genomics Ltd
OTC:ROSGQ
Rosetta Genomics Ltd
Net Income
Rosetta Genomics Ltd
Net Income Peer Comparison
CLGN
KMDA
URGN
ENTX
Competitive Net Income Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Rosetta Genomics Ltd
OTC:ROSGQ
|
Net Income
-$16.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Net Income
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income
$12.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income
-$104.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income
-$8.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Net Income
-₪28.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
See Also
What is Rosetta Genomics Ltd's Net Income?
Net Income
-16.2m
USD
Based on the financial report for Dec 31, 2016, Rosetta Genomics Ltd's Net Income amounts to -16.2m USD.
What is Rosetta Genomics Ltd's Net Income growth rate?
Net Income CAGR 5Y
-10%
Over the last year, the Net Income growth was 6%. The average annual Net Income growth rates for Rosetta Genomics Ltd have been -8% over the past three years , -10% over the past five years .
You don't have any saved screeners yet
